Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.

PMID:
9747868
2.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
3.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
4.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, DeschĂȘnes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL.

J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42.

PMID:
8901851
5.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
6.

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM.

J Natl Cancer Inst. 1994 Apr 6;86(7):527-37.

PMID:
8133536
7.
8.

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.

Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group.

J Natl Cancer Inst. 2003 Jan 15;95(2):160-5.

PMID:
12529349
9.

National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):495S-501S. Review.

10.

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group.

J Natl Cancer Inst. 2007 May 2;99(9):727-37.

PMID:
17470740
11.

Coronary heart disease mortality and adjuvant tamoxifen therapy.

Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J.

J Natl Cancer Inst. 1997 Jun 4;89(11):776-82.

PMID:
9182975
13.
14.

The cost effectiveness of tamoxifen in the prevention of breast cancer.

Noe LL, Becker RV 3rd, Gradishar WJ, Gore M, Trotter JP.

Am J Manag Care. 1999 Jun;5(6 Suppl):S389-406.

15.
16.

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 2006 Jul 5;98(13):904-10.

PMID:
16818854
17.

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N.

J Natl Cancer Inst. 2004 Apr 7;96(7):516-23.

PMID:
15069113
18.
19.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG.

J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82.

PMID:
9390536
20.

Chemoprevention for high-risk women: tamoxifen and beyond.

Fabian CJ, Kimler BF.

Breast J. 2001 Sep-Oct;7(5):311-20. Review.

PMID:
11906441

Supplemental Content

Support Center